In addition, ligand-like inhibitors of GP IIb/IIIa used in current clinical practice, after binding to GP IIb/IIIa, can induce conformational changes, causing severe thrombocytopenia or paradoxical platelet activation [56]. Here, ITGA2B is linked to Thrombocytopenia.